Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576576 | 0.85 | PTGDR2 (0.41) | DPP4 | |
| SCHEMBL5576875 | 0.84 | ALDH1A1 (0.50) | MAPK8ALDH1A1SMN1; SMN2 | |
| SCHEMBL5576858 | 0.82 | MAPT (0.43) | MAPK8ALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL5238679 | 0.80 | ALDH1A1 (0.50) | MAPK8ALDH1A1SMN1; SMN2 | |
| SCHEMBL5577145 | 0.80 | PTGDR2 (0.43) | DPP4 | |
| SCHEMBL5238730 | 0.77 | LMNA (0.41) | MAPK8ALDH1A1 | |
| SCHEMBL5235788 | 0.72 | KDM4E (0.41) | MAPK8ALDH1A1SMN1; SMN2 | |
| SCHEMBL5233862 | 0.70 | KDM4E (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12933338 | 0.69 | MEN1 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5235750 | 0.69 | ADORA3 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | EGLN1 1334/4885MAPK8 1528/4885ALDH1A1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.